Jump To

Botox Dosage

Generic name: onabotulinumtoxinA
Brand names: Botox, Botox Cosmetic
Drug class: Skeletal muscle relaxants

Medically reviewed by  A Ras MD.

 

Adult Dosing

Dosage forms:  INJ

Special Note

[dosing clarification]
Info: max cumulative dose is 400 units q12wk when using onabotulinumtoxinA for 1 or more indications

Overactive bladder

[100 units IM divided in 20 sites x1]
Info: may repeat no more frequently than q12wk

Detrusor overactivity, neurogenic

[200 units IM divided in 30 sites x1]
Info: may repeat no more frequently than q12wk

Migraine headache prophylaxis

[155 units IM divided in 31 sites q12wk]
Info: see pkg insert for dose per site

Upper limb spasticity

[biceps brachii]
Dose: 60-200 units IM divided in 2-4 sites x1; Max: 50 units/site; Info: individualize dose based on spasticity severity, presence of local muscle weakness, prior response or adverse rxns; may repeat no more frequently than q12wk
[brachioradialis]
Dose: 45-75 units IM divided in 1-2 sites x1; Max: 50 units/site; Info: individualize dose based on spasticity severity, presence of local muscle weakness, prior response or adverse rxns; may repeat no more frequently than q12wk
[brachialis]
Dose: 30-50 units IM divided in 1-2 sites x1; Max: 50 units/site; Info: individualize dose based on spasticity severity, presence of local muscle weakness, prior response or adverse rxns; may repeat no more frequently than q12wk
[pronator teres]
Dose: 15-25 units IM in 1 site x1; Max: 50 units/site; Info: individualize dose based on spasticity severity, presence of local muscle weakness, prior response or adverse rxns; may repeat no more frequently than q12wk
[pronator quadratus]
Dose: 10-50 units IM in 1 site x1; Max: 50 units/site; Info: individualize dose based on spasticity severity, presence of local muscle weakness, prior response or adverse rxns; may repeat no more frequently than q12wk
[flexor carpi radialis or ulnaris]
Dose: 12.5-50 units IM in 1 site x1; Max: 50 units/site; Info: individualize dose based on spasticity severity, presence of local muscle weakness, prior response or adverse rxns; may repeat no more frequently than q12wk
[flexor digitorum profundus or sublimis]
Dose: 30-50 units IM in 1 site x1; Max: 50 units/site; Info: individualize dose based on spasticity severity, presence of local muscle weakness, prior response or adverse rxns; may repeat no more frequently than q12wk
[lumbricals or interossei]
Dose: 5-10 units IM in 1 site x1; Max: 50 units/site; Info: individualize dose based on spasticity severity, presence of local muscle weakness, prior response or adverse rxns; may repeat no more frequently than q12wk
[adductor pollicis or flexor pollicis longus]
Dose: 20 units IM in 1 site x1; Max: 50 units/site; Info: individualize dose based on spasticity severity, presence of local muscle weakness, prior response or adverse rxns; may repeat no more frequently than q12wk
[flexor pollicis brevis or opponens pollicis]
Dose: 5-25 units IM in 1 site x1; Max: 50 units/site; Info: individualize dose based on spasticity severity, presence of local muscle weakness, prior response or adverse rxns; may repeat no more frequently than q12wk

Lower limb spasticity

[gastrocnemius medial head, gastrocnemius lateral head, soleus, or tibialis posterior]
Dose: 75 units IM divided in 3 sites x1; Max: 50 units/site; Info: individualize dose based on spasticity severity, presence of local muscle weakness, prior response or adverse rxns; may repeat no more frequently than q12wk
[flexor hallucis longus or flexor digitorum longus]
Dose: 50 units IM divided in 2 sites x1; Max: 50 units/site; Info: individualize dose based on spasticity severity, presence of local muscle weakness, prior response or adverse rxns; may repeat no more frequently than q12wk

Cervical dystonia

[198-300 units IM divided among affected muscles x1]
Max: 50 units/site; Info: individualize dose based on head/neck position, pain localization, muscle hypertrophy, adverse rxns; may repeat after 3mo

Hyperhidrosis, primary axillary

[50 units/axilla intradermally divided in 10-15 sites x1]
Info: repeat when effects diminish

Blepharospasm

[1.25-2.5 units/site IM q3mo]
Max: cumulative dose 200 units/30 days

Strabismus

[1.25-5 units/site IM q3mo]
Max: 25 units/site

Spasmodic dysphonia

[1.25-7.5 units IM divided among affected muscles x1]
Start: 2.5-5 units IM divided among affected muscles x1; Info: individualize dose; repeat when effects diminish

Renal dosing

[not defined]
renal impairment: not defined
HD/PD: not defined

Hepatic dosing

[not defined]

 

 

SRC: NLM .

Read Next Article

PHP Code Snippets Powered By : XYZScripts.com